Showing 5511-5520 of 6964 results for "".
- MC2 Partners with EPI for Commercialization of Wynzorahttps://practicaldermatology.com/news/mc2-partners-partners-with-epi-for-commercialization-of-wynzora/2460510/MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. Wynzora Cream was approvedby the FDA last month for the topical treatment of plaque psoriasis in adult
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- NuFace Names New CEOhttps://practicaldermatology.com/news/nuface-names-new-ceo/2460504/Michael Larrain is the new Chief Executive Officer at NuFACE. Tera Peterson, former CEO, will remain at the company as Co-Founder, Chairman of the Board and Chief Creative Officer. Larrain was CEO at PCA Skin and held seve
- InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technologyhttps://practicaldermatology.com/news/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology/2460501/InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform. Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu
- Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatologyhttps://practicaldermatology.com/news/verrica-enters-agreement-with-lytix-for-oncolytic-peptide-for-dermatology/2460498/Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinoma
- SoftWave Tissue Regeneration Technologies Takes On Cellulitehttps://practicaldermatology.com/news/softwave-tissue-regeneration-technologies-takes-on-cellulite/2460494/SoftWave Tissue Regeneration Technologies plans to start a 60-patient study to evaluate the safety and efficacy of the DermaGold device for the temporary improvement in the appearance of cellulite. The company has a pa
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Rihanna Introduces Fenty Skinhttps://practicaldermatology.com/news/rihanna-introduces-fenty-skin/2460487/Rihanna, in partnership with Kendo Brands, is rolling out Fenty Skin. After years of feeling overwhelmed by all the skincare choices and a bad experience with a product that discolored her skin as a teen, Rihanna dreamed of creating a line that was easy and effective. Now, she'
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus.&